Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism

The microsomal antiestrogen-binding site (AEBS) is a high-affinity membranous binding site for the antitumor drug tamoxifen that selectively binds diphenylmethane derivatives of tamoxifen such as PBPE and mediates their antiproliferative properties. The AEBS is a hetero-oligomeric complex consisting of 3β-hydroxysterol-Δ8-Δ7-isomerase and 3β-hydroxysterol-Δ7-reductase. High-affinity AEBS ligands inhibit these enzymes leading to the massive intracellular accumulation of zymostenol or 7-dehydrocholesterol (DHC), thus linking AEBS binding to the modulation of cholesterol metabolism and growth control. The aim of the present study was to gain more insight into the control of breast cancer cell growth by AEBS ligands. We report that PBPE and tamoxifen treatment induced differentiation in human breast adenocarcinoma cells MCF-7 as indicated by the arrest of cells in the G0-G1 phase of the cell cycle, the increase in the cell volume, the accumulation and secretion of lipids, and a milk fat globule protein found in milk. These effects were observed with other AEBS ligands and with zymostenol and DHC. Vitamin E abrogates the induction of differentiation and reverses the control of cell growth produced by AEBS ligands, zymostenol, and DHC, showing the importance of the oxidative processes in this effect. AEBS ligands induced differentiation in estrogen receptor-negative mammary tumor cell lines SKBr-3 and MDA-MB-468 but with a lower efficiency than observed with MCF-7. Together, these data show that AEBS ligands exert an antiproliferative effect on mammary cancer cells by inducing cell differentiation and growth arrest and highlight the importance of cholesterol metabolism in these effects. [Mol Cancer Ther 2008;7(12):3707–18]

[1]  Gilles Favre,et al.  Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. , 2004, Current medicinal chemistry. Anti-cancer agents.

[2]  J. Carroll,et al.  Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. , 2003, Endocrinology.

[3]  M. Aviram,et al.  Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E. , 2002, Atherosclerosis.

[4]  N. Rosen,et al.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. , 2001, Cancer research.

[5]  K. Gelmon,et al.  Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Vincent.  Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. , 2006, Medical hypotheses.

[7]  Paul T. Tarr,et al.  ATP-binding cassette transporter G1 and lipid homeostasis , 2006, Current opinion in lipidology.

[8]  C. Blaha,et al.  OSBP Is a Cholesterol-Regulated Scaffolding Protein in Control of ERK 1 / 2 Activation , 2022 .

[9]  J. Périé,et al.  Synthesis, binding and structure-affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). , 2000, Bioorganic & medicinal chemistry.

[10]  F. Chevy,et al.  Coupled assay of sphingomyelin and ceramide molecular species by gas liquid chromatography. , 2002, Journal of lipid research.

[11]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[12]  T. W. Keenan,et al.  Intracellular origin and secretion of milk fat globules. , 2005, European journal of cell biology.

[13]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[14]  E. Huberman,et al.  Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. , 1992, Biochemical and biophysical research communications.

[15]  L. J. Brandes.  A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological role. , 1984, Biochemical and biophysical research communications.

[16]  M. Jauhiainen,et al.  The OSBP-related proteins (ORPs): global sterol sensors for co-ordination of cellular lipid metabolism, membrane trafficking and signalling processes? , 2006, Biochemical Society transactions.

[17]  G. Schmitz,et al.  Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. , 1991, Journal of lipid research.

[18]  Human Cell Culture , 2002 .

[19]  J. Ranstam,et al.  Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96 973 women without the disease , 2002, The Lancet.

[20]  Y. Lee,et al.  Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells , 2000, Cell Death and Differentiation.

[21]  T. Powles,et al.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.

[22]  H. Vosper,et al.  The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.

[23]  M. Poirot,et al.  Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity. , 1999, Biochemical pharmacology.

[24]  M. Oulad-Abdelghani,et al.  Molecular Characterization of the Microsomal Tamoxifen Binding Site* , 2004, Journal of Biological Chemistry.

[25]  M. Neville,et al.  Lipid Synthesis in Lactation: Diet and the Fatty Acid Switch , 2007, Journal of Mammary Gland Biology and Neoplasia.

[26]  H. Pelicano,et al.  Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. , 2007, Cancer research.

[27]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[28]  G. Mills,et al.  Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward , 2006, Clinical Cancer Research.

[29]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[30]  Katherine D Dugan,et al.  Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. , 2006, Cell metabolism.

[31]  Ping-yuan Wang,et al.  OSBP Is a Cholesterol-Regulated Scaffolding Protein in Control of ERK1/2 Activation , 2005, Science.

[32]  L. Kangas,et al.  Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Favre,et al.  Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells , 2004, Journal of Pharmacology and Experimental Therapeutics.

[34]  M. C. Rudolph,et al.  Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! , 2007, Breast Cancer Research.

[35]  J. Gerrard,et al.  Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated phosphorylation. , 1988, Cancer research.

[36]  A. Matin,et al.  Interactions of sterols with antiestrogen-binding sites: structural requirements for high-affinity binding. , 1989, Journal of lipid research.

[37]  S. Ylä-Herttuala,et al.  Oxysterol Binding Protein Induces Upregulation of SREBP-1c and Enhances Hepatic Lipogenesis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[38]  G. Favre,et al.  The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors , 2006, Journal of Pharmacology and Experimental Therapeutics.

[39]  D. Vigushin,et al.  The nuclear oxysterol receptor LXRα is expressed in the normal human breast and in breast cancer , 2004, Medical oncology.

[40]  B. Perret,et al.  Hepatic lipase induces the formation of pre-beta 1 high density lipoprotein (HDL) from triacylglycerol-rich HDL2. A study comparing liver perfusion to in vitro incubation with lipases. , 1994, The Journal of biological chemistry.

[41]  H. Nakamura,et al.  Tumor-targeted induction of oxystress for cancer therapy , 2007, Journal of drug targeting.

[42]  R. Lüllmann-Rauch,et al.  Lipidosis induced by amphiphilic cationic drugs. , 1978, Biochemical pharmacology.

[43]  J. McManaman,et al.  Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation Published, JLR Papers in Press, April 16, 2003. DOI 10.1194/jlr.M300045-JLR200 , 2003, Journal of Lipid Research.

[44]  G. Schroepfer,et al.  Oxysterols: modulators of cholesterol metabolism and other processes. , 2000, Physiological reviews.

[45]  L. Murphy,et al.  High-affinity anti-oestrogen binding site distinct from the oestrogen receptor , 1980, Nature.